CN Patent

CN112321673B — 一种前列腺特异性膜抗原靶向抑制剂及应用和探针

Assigned to Peking University First Hospital · Expires 2022-09-20 · 4y expired

What this patent protects

本发明属于核医学领域，涉及一种前列腺特异性膜抗原靶向抑制剂及应用和探针。该抑制剂为具有式I所示结构化合物中的至少一种。本发明提供的靶向PSMA的探针 68 Ga‑DXJ149和 68 Ga‑DXJ155是两种非常有潜力的三七素类 68 Ga标记PSMA靶向分子探针，特别是 68 Ga‑DXJ149在肿瘤摄取和体内代谢等方面均优于临床研究常用PSMA靶向探针 68 Ga‑PSMA617，具有较大的临床转化价值。

USPTO Abstract

本发明属于核医学领域，涉及一种前列腺特异性膜抗原靶向抑制剂及应用和探针。该抑制剂为具有式I所示结构化合物中的至少一种。本发明提供的靶向PSMA的探针 68 Ga‑DXJ149和 68 Ga‑DXJ155是两种非常有潜力的三七素类 68 Ga标记PSMA靶向分子探针，特别是 68 Ga‑DXJ149在肿瘤摄取和体内代谢等方面均优于临床研究常用PSMA靶向探针 68 Ga‑PSMA617，具有较大的临床转化价值。

Drugs covered by this patent

Patent Metadata

Patent number
CN112321673B
Jurisdiction
CN
Classification
—
Expires
2022-09-20
Drug substance claim
No
Drug product claim
No
Assignee
Peking University First Hospital
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.